SubjectVerb relationObjectSentenceSentimentTitleUrlDate
Coherus intends to launch biosimilar Udenyca on Jan Coherus intends to launch the biosimilar Udenyca on Jan NeutralCoherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Incs infectionfighting treatment Neulasta at a 33 percent discount http://www.reuters.com/news/health/article/us-coherus-biosimilar/coherus-prices-biosimilar-to-amgens-neulasta-at-33-percent-discount-idUSKCN1ND36Q2018-11-09